Innoviva, Inc. - Common Stock (NQ:INVA)

21.12 +0.18 (+0.86%)

Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Innoviva, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 09, 2023

From Innoviva, Inc.

Via Business Wire

5 Value Stocks In The Healthcare Sector ↗

May 08, 2023

Via Benzinga

Innoviva Announces Retirement of Board Chairman

April 28, 2023

From Innoviva, Inc.

Via Business Wire

Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories ↗

April 18, 2023

Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs

Via Benzinga

FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections ↗

April 18, 2023

Via Benzinga

What 4 Analyst Ratings Have To Say About Innoviva ↗

March 03, 2023

Via Benzinga

Innoviva Earnings Perspective: Return On Capital Employed ↗

December 19, 2022

Via Benzinga

Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee

April 17, 2023

From Innoviva, Inc.

Via Business Wire

Innoviva Stock Trading Halted Today

April 17, 2023

From Innoviva, Inc.

Via Business Wire

Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic

March 13, 2023

From Innoviva, Inc.

Via Business Wire

Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress

February 28, 2023

From Innoviva, Inc.

Via Business Wire

Four Undervalued Healthcare Stocks for 2023

January 06, 2023

These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.

Via MarketBeat

Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)

November 30, 2022

From Innoviva, Inc.

Via Business Wire

Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

November 09, 2022

From Innoviva, Inc.

Via Business Wire

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022

October 19, 2022

--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints

From Entasis Therapeutics Holdings Inc.

Via GlobeNewswire

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

October 12, 2022

Six abstracts selected for presentation, including three oral presentations

From Entasis Therapeutics Holdings Inc.

Via GlobeNewswire

A Look Into Healthcare Sector Value Stocks ↗

October 03, 2022

The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...

Via Benzinga

Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings ↗

September 19, 2022

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

September 19, 2022

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...

Via Benzinga

Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

September 08, 2022

From Innoviva, Inc.

Via Business Wire

3 No-Brainer Stocks Under $10 to Buy for September ↗

September 02, 2022

Cash-rich investors have the flexibility to buy no-brainer penny stocks to boost overall returns in a risk-adverse environment.

Via InvestorPlace

Innoviva Completes Acquisition of La Jolla Pharmaceutical

August 22, 2022

From Innoviva, Inc.

Via Business Wire

Innoviva's Return On Capital Employed Overview ↗

August 01, 2022

Pulled from Benzinga Pro data, Innoviva (NASDAQ:INVA) showed a loss in earnings since Q1, totaling $21.37 million. Sales, on the other hand, increased by 20.17% to $108.22 million during Q2.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

July 28, 2022

On Thursday, 108 companies set new 52-week lows.

Via Benzinga

Innoviva: Q2 Earnings Insights ↗

July 27, 2022

Innoviva (NASDAQ:INVA) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Innoviva missed estimated earnings...

Via Benzinga

Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

July 27, 2022

From Innoviva, Inc.

Via Business Wire

Overview Of Value Stocks In The Healthcare Sector ↗

July 25, 2022

What is a Value Stock?

Via Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗

July 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗

July 20, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 13, 2022

Gainers

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.